amcure Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $2.07M
Latest Deal Amount
  • Investors
  • 7

amcure General Information

Description

Developer of medical compounds intended to offer treatment for highly metastatic forms of cancer. The company's compounds include advanced development candidate, AMC303, which uses peptide-based compounds that target one highly specific co-receptor, CD44v6, which blocks several relevant oncological pathways (VEGF/VEGFR-2, HGF/c-Met, and MSP/RON) involved in tumor growth, angiogenesis and the development and regression of metastases, enabling doctors to advance in the treatment of pancreatic cancer, head cancer, neck cancer, gastric cancer, colorectal cancer, breast cancer and lung cancer.

Contact Information

Website
www.amcure.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Herrmann-von-Helmholtz-Platz 1
  • 76344 Eggenstein-Leopoldshafen
  • Germany
+49 07247 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

amcure Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Grant 31-Aug-2017 $2.07M 000.00 Completed Generating Revenue
5. Early Stage VC (Series B) 14-Dec-2016 00.000 000.00 000.00 Completed Generating Revenue
4. Grant 01-Dec-2015 00.000 000.00 Completed Generating Revenue
3. Early Stage VC (Series A) 15-Jul-2014 00.000 000.00 Completed Generating Revenue
2. Early Stage VC $10.4M $15.6M Completed Startup
1. Early Stage VC $5.2M $5.2M Completed Startup
To view amcure’s complete valuation and funding history, request access »

amcure Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of medical compounds intended to offer treatment for highly metastatic forms of cancer. The company's compound
Drug Discovery
Eggenstein-Leopoldshafen, Germany
6 As of 2021
000.00
0000000000 000.00

00000 00

um dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qu
0000000000000
Waltham, MA
00 As of 0000
00000
0000 0000-00-00
00000000 00000

0000000

eniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute
0000 000000000
Palo Alto, CA
0 As of 0000
00.00
000 0000-00-00
00000000000 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

amcure Competitors (64)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TScan Therapeutics Formerly VC-backed Waltham, MA 00 00000 00000000 00000
0000000 00000000 Venture Capital-Backed Palo Alto, CA 0 00.00 00000000000 00.00
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000 Venture Capital-Backed Utrecht, Netherlands 00 00.000 0000000000 0 00.000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 64 competitors. Get the full list »

amcure Executive Team (5)

Name Title Board Seat Contact Info
Klaus Dembowsky Ph.D Chief Executive Officer
Véronique Orian-Rousseau Ph.D Co-Founder & Scientific Advisory Board Member
Alexandra Matzke-Ogi Ph.D Co-Founder & Head of Exploratory Research
Heinz Schwer Ph.D Advisor
You’re viewing 4 of 5 executive team members. Get the full list »

amcure Board Members (1)

Name Representing Role Since
Harald Poth Ph.D LBBW Venture Capital Board Member 000 0000
To view amcure’s complete board members history, request access »

amcure Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

amcure Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Karlsruhe Institute of Technology University Minority 000 0000 000000 0
German Ministry of Education and Research Government 000 0000 000000 0
BioM Biotech Cluster Development Accelerator/Incubator Minority 000 0000 000000 0
KfW Group Investment Bank Minority 000 0000 000000 0
LBBW Venture Capital Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »